Abstract
The expression of N-glycolylneuraminic acid forming the structure of gangliosides and/or other glycoconjugates (Hanganutziu-Deicher antigen) in human has been considered as a tumor-associated antigen. Specifically, some reports of 14F7 Mab (a highly specific Mab raised against N-glycolyl GM3 ganglioside) reactivity in human tumors have been recently published. Nevertheless, tumors of epithelial origin have been mostly evaluated. The goal of the present paper was to evaluate the immunohistochemical recognition of 14F7 Mab in different human tumors of neuroectodermal, mesodermal, and epithelial origins using an immunoperoxidase staining method. Samples of fetal, normal, and reactive astrocytosis of the brain were also included in the study. In general, nontumoral tissues, as well as, low-grade brain tumors showed no or a limited immunoreaction with 14F7 Mab. Nevertheless, high-grade astrocytomas (III-IV) and neuroblastomas, as well as, sarcomas and thyroid carcinomas were mostly reactive with 14F7. No reaction was evidenced in medulloblastomas and ependymoblastomas. Our data suggest that the expression of N-glycolyl GM3 ganglioside could be related to the aggressive behavior of malignant cells, without depending on the tumor orig...Continue Reading
References
Nov 21, 1977·Biochemical and Biophysical Research Communications·H HigashiK Okouchi
Sep 1, 1992·Neurosurgery·N ShinouraM Oshima
May 6, 1996·FEBS Letters·W SchlenzkaR Schauer
Dec 1, 1995·Hybridoma·A M VázquezC Alvarez
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·H H ChouA Varki
Jul 1, 1999·Journal of Neurochemistry·J A EcsedyT N Seyfried
Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·T YamashitaR L Proia
Aug 22, 2000·Hybridoma·A CarrL E Fernández
Apr 20, 2001·British Journal of Cancer·M NordsmarkJ Overgaard
Aug 15, 2001·European Journal of Biochemistry·C OetkeO T Keppler
Aug 28, 2001·Biochimie·Y N MalykhL Shaw
Oct 11, 2002·Neurochemical Research·Guido KohlaRoland Schauer
Oct 3, 2003·Proceedings of the National Academy of Sciences of the United States of America·Pam TangvoranuntakulElaine Muchmore
Nov 24, 2004·The Journal of Biological Chemistry·Muriel BardorAjit Varki
Oct 7, 2005·Cancer Immunology, Immunotherapy : CII·Joel de LeònLuis E Fernández
Dec 3, 2005·Breast Cancer Research and Treatment·Juan P OlivaLuis E Fernández
Mar 17, 2006·Cancer Research·Jun YinReiji Kannagi
May 25, 2006·Acta histochemica·Pavel BabálEva Brabencová
Mar 4, 2008·International Immunology·Joel de LeónLuis E Fernández
Jan 20, 2009·Reviews on Recent Clinical Trials·Daniel Osuna, Enrique de Alava
May 16, 2009·Current Cancer Drug Targets·Verena Amberger-Murphy
Jun 13, 2009·BMC Cancer·Hester van CruijsenGiuseppe Giaccone
Jul 19, 2011·Journal of Thyroid Research·Natalie BurrowsGeorg Brabant
Sep 24, 2011·Clinical & Developmental Immunology·Alejandra M ScursoniMaría Teresa G de Dávila
Oct 13, 2011·ISRN Gastroenterology·Rancés BlancoAdriana Carr
Mar 1, 2012·ISRN Dermatology·Rancés BlancoAdriana Carr
Apr 7, 2012·Pathology Research International·Rancés BlancoAdriana Carr
Citations
Jul 11, 2019·Scientific Reports·Denise DorvignitStephan von Gunten
Jan 2, 2014·Pathology Research International·Rancés BlancoEnrique Rengifo
Dec 10, 2014·Cellular and Molecular Life Sciences : CMLS·Kayluz Frias BoliganStephan von Gunten
Jun 12, 2019·BMC Cancer·Daniel Pilco-JanetaAdriana Carr
May 7, 2019·Frontiers in Immunology·Chirag DharAjit Varki
Jul 17, 2020·Journal of Oncology·Necdet UskentAziz Yazar
Apr 3, 2013·Glycoconjugate Journal·Ana Victoria CasadesúsAlejandro López-Requena
Oct 18, 2019·Frontiers in Immunology·Shweta TiwaryMasaki Terabe